NMRA Neumora Therapeutics Inc.
Price (delayed)
$11.94
Market cap
$1.91B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.89
Enterprise value
$1.76B
Highlights
The company's EPS has surged by 58% YoY and by 33% QoQ
The debt has contracted by 47% YoY and by 19% from the previous quarter
Neumora Therapeutics's equity has surged by 174% YoY but it has decreased by 10% QoQ
Neumora Therapeutics's quick ratio has increased by 29% YoY but it has decreased by 6% QoQ
The net income has dropped by 108% year-on-year and by 8% since the previous quarter
Key stats
What are the main financial stats of NMRA
Market
Valuations
Earnings
Shares outstanding
160.03M
Market cap
$1.91B
Enterprise value
$1.76B
Price to earnings (P/E)
N/A
Price to book (P/B)
5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$273.79M
EBITDA
-$269.79M
Free cash flow
-$198.41M
Per share
Balance sheet
Liquidity
EPS
-$1.89
Free cash flow per share
-$1.25
Book value per share
$2.39
Revenue per share
$0
TBVPS
$2.54
Total assets
$404.47M
Total liabilities
$23.21M
Debt
$3.61M
Equity
$381.26M
Working capital
$375.19M
Debt to equity
0.01
Current ratio
17.22
Quick ratio
16.12
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57.9%
Return on equity
-61.4%
Return on invested capital
-159.1%
Return on capital employed
-71.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NMRA stock price
How has the Neumora Therapeutics stock price performed over time
Intraday
-0.75%
1 week
4.65%
1 month
5.94%
1 year
-26.52%
YTD
-29.97%
QTD
21.46%
Financial performance
How have Neumora Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$294.76M
Net income
-$274.18M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 108% year-on-year and by 8% since the previous quarter
Neumora Therapeutics's operating income has shrunk by 107% YoY and by 8% QoQ
Growth
What is Neumora Therapeutics's growth rate over time
Valuation
What is Neumora Therapeutics stock price valuation
P/E
N/A
P/B
5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 58% YoY and by 33% QoQ
Neumora Therapeutics's equity has surged by 174% YoY but it has decreased by 10% QoQ
The stock's P/B is 7% above its last 4 quarters average of 4.7
Efficiency
How efficient is Neumora Therapeutics business performance
NMRA's return on invested capital has dropped by 64% year-on-year but it is up by 7% since the previous quarter
The ROA has plunged by 58% YoY and by 5% from the previous quarter
The ROE has grown by 46% from the previous quarter
Dividends
What is NMRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NMRA.
Financial health
How did Neumora Therapeutics financials performed over time
NMRA's current ratio is up by 33% year-on-year but it is down by 4.3% since the previous quarter
Neumora Therapeutics's quick ratio has increased by 29% YoY but it has decreased by 6% QoQ
The debt is 99% less than the equity
Neumora Therapeutics's debt to equity has surged by 200% YoY
Neumora Therapeutics's equity has surged by 174% YoY but it has decreased by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.